Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Paradies, Valeria (26431508400)"

Filter results by typing the first few letters
Now showing 1 - 5 of 5
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk
    (2022)
    Smits, Pieter C. (35952782900)
    ;
    Frigoli, Enrico (36702683200)
    ;
    Vranckx, Pascal (6603261242)
    ;
    Ozaki, Yukio (57192966790)
    ;
    Morice, Marie-Claude (7005332224)
    ;
    Chevalier, Bernard (12772595100)
    ;
    Onuma, Yoshinobu (15051093400)
    ;
    Windecker, Stephan (7003473419)
    ;
    Tonino, Pim A.L. (23020530900)
    ;
    Roffi, Marco (7004532440)
    ;
    Lesiak, Maciej (57208415591)
    ;
    Mahfoud, Felix (26428326200)
    ;
    Bartunek, Jozef (7006397762)
    ;
    Hildick-Smith, David (8089365300)
    ;
    Colombo, Antonio (35354455800)
    ;
    Stankovic, Goran (59150945500)
    ;
    Iñiguez, Andrés (7005329352)
    ;
    Schultz, Carl (7202476533)
    ;
    Kornowski, Ran (16947378300)
    ;
    Ong, Paul J.L. (7102312670)
    ;
    Alasnag, Mirvat (24479281000)
    ;
    Rodriguez, Alfredo E. (35515288300)
    ;
    Paradies, Valeria (26431508400)
    ;
    Kala, Petr (57203043232)
    ;
    Kedev, Sasko (23970691700)
    ;
    Al Mafragi, Amar (57188690658)
    ;
    Dewilde, Willem (16549215600)
    ;
    Heg, Dik (6701630557)
    ;
    Valgimigli, Marco (57222377628)
    Background: The optimal duration of antiplatelet therapy (APT) after coronary stenting in patients at high bleeding risk (HBR) presenting with an acute coronary syndrome remains unclear. Objectives: The objective of this study was to investigate the safety and efficacy of an abbreviated APT regimen after coronary stenting in an HBR population presenting with acute or recent myocardial infarction. Methods: In the MASTER DAPT trial, 4,579 patients at HBR were randomized after 1 month of dual APT (DAPT) to abbreviated (DAPT stopped and 11 months single APT or 5 months in patients with oral anticoagulants) or nonabbreviated APT (DAPT for minimum 3 months) strategies. Randomization was stratified by acute or recent myocardial infarction at index procedure. Coprimary outcomes at 335 days after randomization were net adverse clinical outcomes events (NACE); major adverse cardiac and cerebral events (MACCE); and type 2, 3, or 5 Bleeding Academic Research Consortium bleeding. Results: NACE and MACCE did not differ with abbreviated vs nonabbreviated APT regimens in patients with an acute or recent myocardial infarction (n = 1,780; HR: 0.83; 95% CI: 0.61-1.12 and HR: 0.86; 95% CI: 0.62-1.19, respectively) or without an acute or recent myocardial infarction (n = 2,799; HR: 1.03; 95% CI: 0.77-1.38 and HR: 1.13; 95% CI: 0.80-1.59; Pinteraction = 0.31 and 0.25, respectively). Bleeding Academic Research Consortium 2, 3, or 5 bleeding was significantly reduced in patients with or without an acute or recent myocardial infarction (HR: 0.65; 95% CI: 0.46-0.91 and HR: 0.71; 95% CI: 0.54-0.92; Pinteraction = 0.72) with abbreviated APT. Conclusions: A 1-month DAPT strategy in patients with HBR presenting with an acute or recent myocardial infarction results in similar NACE and MACCE rates and reduces bleedings compared with a nonabbreviated DAPT strategy. (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; NCT03023020) © 2022 The Authors
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Call to action for acute myocardial infarction in women: International multi-disciplinary practical roadmap
    (2024)
    Manzo-Silberman, Stephane (22985709500)
    ;
    Hawranek, Michal (16642939400)
    ;
    Banerjee, Shrilla (55477349000)
    ;
    Kaluzna-Oleksy, Marta (55070797200)
    ;
    Alasnag, Mirvat (24479281000)
    ;
    Paradies, Valeria (26431508400)
    ;
    Parapid, Biljana (6506582242)
    ;
    Sabouret, Pierre (6602435498)
    ;
    Wolczenko, Agnieszka (59161603400)
    ;
    Kunadian, Vijay (55390915800)
    ;
    Uchmanowicz, Izabella (28268113500)
    ;
    Nizard, Jacky (7004283473)
    ;
    Gilard, Martine (7003954275)
    ;
    Mehran, Roxana (7004992409)
    ;
    Chieffo, Alaide (57202041611)
    Cardiovascular diseases are the leading cause of death among women, and the incidence among younger women has shown the greatest increase over the last decades, in particular for acute myocardial infarction (AMI). Moreover, the prognosis of women post-AMI is poor when compared with men of similar ages. Since the 1990s, an abundant literature has highlighted the existing differences between sexes with regard to presentation, burden, and impact of traditional risk factors and of risk factors pertaining predominantly to women, the perception of risk by women and men, and the pathophysiological causations, their treatment, and prognosis. These data that have been accumulated over recent years highlight several targets for improvement. The objective of this collaborative work is to define the actions required to reverse the growing incidence of AMI in women and improve the patient pathway and care, as well as the prognosis. We aim to provide practical toolkits for different health professionals involved in the care of women, so that each step, from cardiovascular risk assessment to symptom recognition, to the AMI pathway and rehabilitation, thus facilitating that from prevention to intervention of AMI, can be optimized. © 2024 The Author(s). Published by Oxford University Press on behalf of the European Society of Cardiology.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    International consensus statement on challenges for women in cardiovascular practice and research in the CoVid-19 era
    (2022)
    Öz, Tuğba Kemaloğlu (55804564100)
    ;
    Cader, F. Aaysha (56312554700)
    ;
    Dakhil, Zainab A. (6507164761)
    ;
    Parapid, Biljana (6506582242)
    ;
    Kadavath, Sabeeda (55927840800)
    ;
    Bond, Rachel (56697934100)
    ;
    Chieffo, Alaide (57202041611)
    ;
    Gimelli, Alessia (6603051677)
    ;
    Mihailidou, Anastasia S. (57206834213)
    ;
    Ramu, Bhavadharini (48061323800)
    ;
    Cavarretta, Elena (14051627100)
    ;
    Michos, Erin D. (6506845117)
    ;
    Kaya, Esra (58082979000)
    ;
    Buchanan, Louise (56041610600)
    ;
    Patil, Mansi (57217715499)
    ;
    Aste, Milena (55827464300)
    ;
    Alasnag, Mirvat (24479281000)
    ;
    Babazade, Nigar (57219005510)
    ;
    Burgess, Sonya (55362621500)
    ;
    Manzo-Silberman, Stéphane (22985709500)
    ;
    Paradies, Valeria (26431508400)
    ;
    Thamman, Ritu (6503929350)
    The challenges to academic and professional development and career advancement of women in cardiology (WiC), imposed by the pandemic, not only impinge the female cardiologists’ “leaky pipeline” but also make the “leakiness” more obvious. This consensus document aims to highlight the pandemic challenges WIC face, raise awareness of the gender equity gap, and propose mitigating actionable solutions derived from the data and experiences of an international group of female cardiovascular clinicians and researchers. This changing landscape has led to the need for highly specialized cardiologists who may have additional training in critical care, imaging, advanced heart failure, or interventional cardiology. Although women account for most medical school graduates, the number of WIC, particularly in mentioned sub-specialties, remains low. Moreover, women have been more affected by systemic issues within these challenging work environments, limiting their professional progression, career advancement, and economic potential. Therefore, it is imperative that tangible action points be noted and undertaken to ensure the representation of women in leadership, advocacy, and decision-making, and increase diversity in academia. Strategies to mitigate the negative impacts of the pandemic need to be taken during this COVID-19 pandemic to ensure WIC have a place in the field of Cardiology. © 2022 Edizioni Minerva Medica.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Prasugrel monotherapy versus standard DAPT in STEMI patients with OCT-guided or angio-guided complete revascularisation: design and rationale of the randomised, multifactorial COMPARE STEMI ONE trial
    (2025)
    Paradies, Valeria (26431508400)
    ;
    Van Mieghem, Nicolas M. (8527971700)
    ;
    Oemrawsingh, Rohit M. (24172653000)
    ;
    Richardt, Gert (7006414918)
    ;
    Esposito, Giovanni (55482395100)
    ;
    Campo, Gianluca (8937083300)
    ;
    Burzotta, Francesco (7003405739)
    ;
    Canova, Paolo (56014422900)
    ;
    Linke, Axel (7006203917)
    ;
    Porto, Italo (6701674096)
    ;
    Trabattoni, Daniela (7006177871)
    ;
    Teeuwen, Koen (41662360800)
    ;
    Adriaenssens, Tom (35261418100)
    ;
    Kala, Petr (57203043232)
    ;
    Stankovic, Goran (59150945500)
    ;
    Vliet, Ria van (59903237300)
    ;
    Giacoppo, Daniele (49863274900)
    ;
    Daemen, Joost (7004485788)
    ;
    Smits, Pieter C. (35952782900)
    Monotherapy with a potent P2Y12 receptor antagonist after 1 month of dual antiplatelet therapy (DAPT) may reduce bleeding in the absence of increased ischaemic events compared to 12-month DAPT in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). PCI guidance with optical coherence tomography (OCT) may enhance stent expansion. COMPARE STEMI ONE is an international, multicentre, open-label, randomised controlled trial. In 1,656 ST-segment elevation myocardial infarction (STEMI) patients, prasugrel monotherapy after 1 month of DAPT, as compared to standard 12-month prasugrel-based DAPT, will be tested for non-inferiority for the primary composite endpoint of net adverse clinical events - defined as all-cause death, myocardial infarction, stroke, or Bleeding Academic Research Consortium Type 3 or 5 bleeding events - at 11 months after randomisation. Furthermore, an ancillary substudy will test the superiority of OCT-guided versus angiography-guided staged complete revascularisation in achieving a larger minimal stent area (MSA) in non-culprit lesions during staged procedures. COMPARE STEMI ONE is the first randomised controlled trial assessing an abbreviated 1-month DAPT regimen followed by prasugrel monotherapy in the context of STEMI. The trial will also study the value of OCT-guided PCI in terms of the MSA of non-culprit lesions and may elucidate potential synergies between intravascular imaging-guided PCI and abbreviated DAPT regimens. (ClinicalTrials.gov: NCT05491200).
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Spontaneous coronary artery dissection in women in the generative period: clinical characteristics, treatment, and outcome—a systematic review and meta-analysis
    (2024)
    Apostolović, Svetlana (13610076800)
    ;
    Ignjatović, Aleksandra (54395417600)
    ;
    Stanojević, Dragana (58530775100)
    ;
    Radojković, Danijela Djordjević (25224580500)
    ;
    Nikolić, Miroslav (57194436285)
    ;
    Milošević, Jelena (59793378300)
    ;
    Filipović, Tamara (57191260384)
    ;
    Kostić, Katarina (56513712400)
    ;
    Miljković, Ivana (26533175300)
    ;
    Djoković, Aleksandra (42661226500)
    ;
    Krljanac, Gordana (8947929900)
    ;
    Mehmedbegović, Zlatko (55778381000)
    ;
    Ilić, Ivan (57210906813)
    ;
    Aleksandrić, Srdjan (35274271700)
    ;
    Paradies, Valeria (26431508400)
    Introduction: Spontaneous coronary artery dissection (SCAD) is a non-traumatic and non-iatrogenic separation of the coronary arterial wall. Materials and methods: This systematic review and meta-analysis is reported following the PRISMA guidelines and is registered in the PROSPERO database. A literature search was focused on female patients in generative period (16–55 of age) with acute coronary syndrome (ACS) caused by SCAD, and comparison from that database NP-SCAD (spontaneous coronary artery dissection in non pregnant women) and P-SCAD (spontaneous coronary artery dissection in pregnant women). Results: 14 studies with 2,145 females in the generative period with ACS caused by SCAD were analyzed. The median age was 41 years (33.4–52.3 years). The most common risk factor was previous smoking history in 24.9% cases. The most common clinical presentation of ACS was STEMI in 47.4%. Conservative treatment was reported in 41.1%. PCI was performed in 32.7%, and 3.8% of patients had CABG surgery. LAD was the most frequently affected (50.5%). The prevalence of composite clinical outcomes including mortality, non-fatal MI and recurrent SCAD was 3.3% (95% CI: 1.4–5.1), 37.7% (95% CI: 1.9–73.4) and 15.2% (95% CI: 9.1–21.3) of patients. P-SCAD compared to NP-SCAD patients more frequently had STEMI (OR = 3.16; 95% CI: 2.30–4.34; I2 = 64%); with the left main and LAD more frequently affected [(OR = 14.34; 95% CI: 7.71–26.67; I2= 54%) and (OR = 1.57; 95% CI: 1.06–2.32; I2= 23%)]; P-SCAD patients more frequently underwent CABG surgery (OR = 6.29; 95% CI: 4.08–9.70; I2= 0%). NP-SCAD compared to P-SCAD patients were more frequently treated conservatevly (OR = 0.61; 95% CI: 0.37–0.98; I2= 0%). In P-SCAD compared to NP-SCAD mortality rates (OR = 1.13; 95% CI: 0.06–21.16; I2= not applicable) and reccurence of coronary artery dissection (OR = 2.54; 95% CI: 0.97–6.61; I2= 0%) were not more prevalent. Conclusion: The results of this meta-analysis indicated that patients with P-SCAD more frequently had STEMI, and events more frequently involved left main and LAD compared to NP-SCAD patients. Women with NP-SCAD were significantly more often treated conservatively compared to P-SCAD patients. P-SCAD compared to NP-SCAD patients did not have significantly higher mortality rates or recurrent coronary dissection. 2024 Apostolović, Ignjatović, Stanojević, Radojković, Nikolić, Milošević, Filipović, Kostić, Miljković, Djoković, Krljanac, Mehmedbegović, Ilić, Aleksandrić and Paradies.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback